MDT

85.34

-1.11%↓

112.28

-1.01%↓

VEEV

169.84

-3.51%↓

HQY

81.94

-1.4%↓

PHR.US

8.2

-2.73%↓

MDT

85.34

-1.11%↓

112.28

-1.01%↓

VEEV

169.84

-3.51%↓

HQY

81.94

-1.4%↓

PHR.US

8.2

-2.73%↓

MDT

85.34

-1.11%↓

112.28

-1.01%↓

VEEV

169.84

-3.51%↓

HQY

81.94

-1.4%↓

PHR.US

8.2

-2.73%↓

MDT

85.34

-1.11%↓

112.28

-1.01%↓

VEEV

169.84

-3.51%↓

HQY

81.94

-1.4%↓

PHR.US

8.2

-2.73%↓

MDT

85.34

-1.11%↓

112.28

-1.01%↓

VEEV

169.84

-3.51%↓

HQY

81.94

-1.4%↓

PHR.US

8.2

-2.73%↓

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

174.94 1.57

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

170.55

Max

176.1

Galvenie mērījumi
By Trading Economics
Ienākumi	-332M -277M
Pārdošana	-11M 994M
Peļņas marža	-27.816
Darbinieki	18,300
EBITDA	730K 198M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+19.36% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-78M 7.9B
Iepriekšējā atvēršanas cena	173.37
Iepriekšējā slēgšanas cena	174.94

Ziņu noskaņojums

By Acuity

11%

89%

16 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. apr. 22:56 UTC

Galvenie ziņu notikumi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026. g. 1. apr. 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026. g. 1. apr. 23:55 UTC

Tirgus saruna

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026. g. 1. apr. 23:43 UTC

Tirgus saruna

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026. g. 1. apr. 23:23 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026. g. 1. apr. 23:07 UTC

Peļņas

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026. g. 1. apr. 23:02 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026. g. 1. apr. 22:39 UTC

Peļņas

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026. g. 1. apr. 22:08 UTC

Tirgus saruna

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026. g. 1. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026. g. 1. apr. 21:31 UTC

Galvenie ziņu notikumi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 1. apr. 20:38 UTC

Peļņas

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026. g. 1. apr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026. g. 1. apr. 20:13 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026. g. 1. apr. 20:07 UTC

Tirgus saruna

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

19.36% augšup

Prognoze 12 mēnešiem

Vidējais 205.89 USD 19.36%

Augstākais 265 USD

Zemākais 175 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

16 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.